Search

Your search keyword '"Laribi K"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Laribi K" Remove constraint Author: "Laribi K"
222 results on '"Laribi K"'

Search Results

1. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

3. Anémies hémolytiques auto-immunes à anticorps chauds associées aux syndromes myélodysplasiques et aux leucémies myélomonocytaires chroniques

5. Cytopénies auto-immunes associées aux hémopathies lymphoïdes B indolentes : une étude de cohorte multicentrique française

6. ZANUBRUTINIB (ZANU) VERSUS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT‐NAïVE (TN) CLL/SLL: EXTENDED FOLLOW‐UP OF THE SEQUOIA STUDY

7. Étude observationnelle prospective sur les Patients attEints de Purpura Thrombopénique Idiopathique (PTI) traités par des agonisTEs des R-TPO (ARTPO) : Eltrombopag et Romiplostim (Étude PEPITE)

8. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

9. S169: CLINICAL AND MOLECULAR MARKERS FOR PREDICTING RESPONSE TO ROMIPLOSTIM TREATMENT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

10. P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY

11. P1632: PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY

12. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

13. Étude observationnelle prospective sur les patients atteints de Purpura Thrombopénique Immunologique (PTI) traités par des agonisTEs des R-TPO (ARTPO): Eltrombopag (EPAG) et Romiplostim (ROMI) (Etude PEPITE)

14. OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY

15. Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (Blood Cancer Journal, (2021), 11, 10, (163), 10.1038/s41408-021-00555-8)

16. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)

18. Maintien à long terme d’une réponse complète avec maladie résiduelle indétectable après une stratégie de traitement combinant de l’ibrutinib à une immunochimiothérapie ≪ adaptée ≫ chez les patients atteints d’une leucémie lymphoïde chronique non antérieurement traitée

19. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

21. Facteurs pronostiques clinico-biologiques et génomiques de la survie dans le syndrome de Richter

23. Caractéristiques cliniques, évolution et prise en charge des thrombopénies immunologiques associées aux syndromes myélodysplasiques et leucémies myélomonocytaires chroniques : une étude multicentrique rétrospective comparative

24. Vénétoclax dans la LLC en rechute ou réfractaire : une étude FILO de la cohorte ATU en France

25. Taux élevé de réponse complète (RC) avec maladie résiduelle (MRD) indétectable dans la moelle après une stratégie d’épargne de chimiothérapie guidée par la MRD en première ligne de traitement dans la leucémie lymphoïde chronique (LLC)

26. A revised international prognostic score system for Waldenström’s macroglobulinemia

29. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

30. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

32. PS1065 OPEN-LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3-MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT

33. PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

34. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

35. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYResearch in context

36. A revised international prognostic score system for Waldenström’s macroglobulinemia

37. OP0053 Inflammatory disorders associated with trisomy 8 myelodysplastic syndromes : french retrospective case control study

39. S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY.

40. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

42. R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS

43. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

44. Results of a Phase II Study of Guadecitabine in Higher Risk MDS Patients Refractory to or Relapsing after Azacitidine Treatment

45. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents

49. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

Catalog

Books, media, physical & digital resources